 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| «12...491492493494495496497498499500501...507508» |
- doxorubicin hydrochloride / Generic mfg.
Enrollment open, Surgery: MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Dec 3, 2013
P=N/A, N=45, Recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting
- ||||| cyclophosphamide / Generic mfg., docetaxel / Generic mfg.
Enrollment closed: Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer (clinicaltrials.gov) - Dec 3, 2013
P3, N=1871, Active, not recruiting, Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||||| Trial completion, Combination therapy: Docetaxel in Breast Cancer (clinicaltrials.gov) - Dec 3, 2013
P3, N=3299, Completed, Sponsor: Sanofi
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- doxorubicin hydrochloride / Generic mfg.
Enrollment change: Comparison Study of Transarterial Chemoembolization and Percutaneous Ethanol Injection for Multiple, Small HCCs (clinicaltrials.gov) - Dec 1, 2013
P3, N=22, Completed, Sponsor: Seoul National University Hospital
Active, not recruiting --> Completed N=284 --> 22
- sorafenib / Generic mfg.
Enrollment open, Metastases: Sorafenib VS TACE in HCC Patients With Portal Vein Invasion (clinicaltrials.gov) - Dec 1, 2013
P2, N=40, Recruiting, Sponsor: Seoul National University Hospital
N=284 --> 22 Active, not recruiting --> Recruiting
- |||||||||| Herceptin (trastuzumab) / Roche
New P3 trial, Metastases: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer (clinicaltrials.gov) - Nov 28, 2013
P3, N=334, Completed, Sponsor: Hoffmann-La Roche
- cisplatin / Generic mfg., cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment open: Additional 4 Cycles of Cisplatin (CDDP4) in Patients With Triple Negative Breast Cancer for Neoadjuvant Chemotherapy (clinicaltrials.gov) - Nov 27, 2013
P2, N=88, Recruiting, Sponsor: Asan Medical Center
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- bortezomib / Generic mfg.
Trial termination: Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment (clinicaltrials.gov) - Nov 25, 2013
P2, N=20, Terminated, Sponsor: University of Iowa
Not yet recruiting --> Recruiting Recruiting --> Terminated; Met study stopping rules
- bortezomib / Generic mfg.
Enrollment change: Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment (clinicaltrials.gov) - Nov 25, 2013
P2, N=20, Terminated, Sponsor: University of Iowa
Recruiting --> Terminated; Met study stopping rules N=87 --> 20
- |||||| Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
Enrollment open: A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) (clinicaltrials.gov) - Nov 25, 2013
P3, N=160, Recruiting, Sponsor: Hoffmann-La Roche
N=87 --> 20 Not yet recruiting --> Recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Metastases: Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors (clinicaltrials.gov) - Nov 25, 2013
P2, N=0, Completed, Sponsor: Societe Internationale d'Oncologie Pediatrique
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Trial completion, Surgery: Combination Chemotherapy Before Surgery in Treating Children With Localized Neuroblastoma (clinicaltrials.gov) - Nov 25, 2013
P3, N=100, Completed, Sponsor: Societe Internationale d'Oncologie Pediatrique
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | carboplatin / Generic mfg., cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion: Chemotherapy in Treating Children With Liver Cancer (clinicaltrials.gov) - Nov 25, 2013
P3, N=260, Completed, Sponsor: Societe Internationale d'Oncologie Pediatrique
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Matulane (procarbazine hydrochloride) / Leadiant Biosci
Trial completion, Metastases: Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Disease (clinicaltrials.gov) - Nov 25, 2013
P3, N=800, Completed, Sponsor: Medical Research Council
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Adcetris (brentuximab vedotin) / Takeda, Pfizer
New P1/2 trial, Combination therapy: Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients (clinicaltrials.gov) - Nov 24, 2013
P1/2, N=10, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
- ||| Polivy (polatuzumab vedotin-piiq) / Roche, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment open, Combination therapy: A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Nov 24, 2013
P1, N=90, Recruiting, Sponsor: Genentech
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment open: Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation (clinicaltrials.gov) - Nov 24, 2013
P2, N=40, Recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- Trial termination, Combination therapy: SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma (clinicaltrials.gov) - Nov 21, 2013
P2, N=6, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Recruiting Active, not recruiting --> Terminated
- Enrollment change, Combination therapy: SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma (clinicaltrials.gov) - Nov 21, 2013
P2, N=6, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated N=54 --> 6
- ||| Polivy (polatuzumab vedotin-piiq) / Roche, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
New P1 trial, Combination therapy: A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Nov 21, 2013
P1, N=90, Recruiting, Sponsor: Genentech
- ||||| Enrollment closed, Metastases: High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma (clinicaltrials.gov) - Nov 19, 2013
P3, N=109, Active, not recruiting, Sponsor: Children's Oncology Group
N=54 --> 6 Completed --> Active, not recruiting
- Xalkori (crizotinib) / Pfizer, Adcetris (brentuximab vedotin) / Takeda, Pfizer
Enrollment open, Combination therapy: Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma (clinicaltrials.gov) - Nov 17, 2013
P2, N=140, Recruiting, Sponsor: National Cancer Institute (NCI)
Completed --> Active, not recruiting Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Biomarker, Enrollment open: Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer (clinicaltrials.gov) - Nov 17, 2013
P2, N=165, Recruiting, Sponsor: Case Comprehensive Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Enrollment change, Combination therapy, Metastases: Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Nov 13, 2013
P1/2, N=102, Completed, Sponsor: Threshold Pharmaceuticals
Not yet recruiting --> Recruiting N=36 --> 102
- |||| evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Trial completion, Combination therapy, Metastases: Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Nov 13, 2013
P1/2, N=102, Completed, Sponsor: Threshold Pharmaceuticals
N=36 --> 102 Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Enrollment open: Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors (clinicaltrials.gov) - Nov 12, 2013
P2, N=47, Recruiting, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||| Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) / Roche, Halozyme
Biomarker, Enrollment open, Metastases: SCHEARLY: A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (clinicaltrials.gov) - Nov 12, 2013
P3, N=240, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment closed, Combination therapy: GAUDI: A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Nov 12, 2013
P1, N=137, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- thioguanine / Generic mfg.
Enrollment closed, IO biomarker: CALGB 10403: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 12, 2013
P2, N=300, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting
- | Trial completion: Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast Cancer (clinicaltrials.gov) - Nov 11, 2013
P3, N=2250, Completed, Sponsor: University Hospital Birmingham
Not yet recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Trial completion: Radiation Therapy Plus Combination Chemotherapy In Treating Patients With Limited Stage Small Cell Lung Cancer (clinicaltrials.gov) - Nov 11, 2013
P3, N=398, Completed, Sponsor: London Lung Cancer Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg., vincristine / Generic mfg.
Trial completion, Surgery: Combination Chemotherapy or Observation Following Surgery in Treating Infants With Neuroblastoma (clinicaltrials.gov) - Nov 11, 2013
P2, N=44, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma (clinicaltrials.gov) - Nov 11, 2013
P3, N=500, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Active, not recruiting --> Completed Active, not recruiting --> Completed
- cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment open: Intraperitoneal Aerosol Chemotherapy in Gastric Cancer (clinicaltrials.gov) - Nov 10, 2013
P2, N=50, Recruiting, Sponsor: Ruhr University of Bochum
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
New P2 trial, Surgery, Metastases: IRCI Gynae Sarcomas, High Grade Uterine Sarcoma (clinicaltrials.gov) - Nov 6, 2013
P2, N=78, Not yet recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
- | Xalkori (crizotinib) / Pfizer, Adcetris (brentuximab vedotin) / Takeda, Pfizer
New P2 trial, Combination therapy: Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma (clinicaltrials.gov) - Nov 6, 2013
P2, N=140, Recruiting, Sponsor: National Cancer Institute (NCI)
- | lenalidomide / Generic mfg.
Enrollment open: MCL R2: R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL (clinicaltrials.gov) - Nov 6, 2013
P3, N=633, Recruiting, Sponsor: The Lymphoma Academic Research Organisation
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- sildenafil / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial suspension: Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers (clinicaltrials.gov) - Nov 5, 2013
P1, N=50, Suspended, Sponsor: Virginia Commonwealth University
Not yet recruiting --> Recruiting Recruiting --> Suspended
- | sorafenib / Generic mfg.
Enrollment open, Metastases: Sorafenib Chemoembolization Evaluation Controlled Trial (clinicaltrials.gov) - Oct 31, 2013
P2/3, N=398, Recruiting, Sponsor: Fourth Military Medical University
Recruiting --> Suspended Not yet recruiting --> Recruiting
- Trial completion: Comparison of Three Combination Chemotherapy Regimens in Treating Women With Stage I or Stage II Breast Cancer (clinicaltrials.gov) - Oct 31, 2013
P2, N=0, Completed, Sponsor: Royal Marsden NHS Foundation Trust
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer (clinicaltrials.gov) - Oct 31, 2013
P3, N=600, Completed, Sponsor: Scottish Cancer Therapy Network
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Imbruvica (ibrutinib) / AbbVie, J&J
New P3 trial, Combination therapy: SELENE : A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov) - Oct 30, 2013
P3, N=400, Recruiting, Sponsor: Janssen Research & Development, LLC
- Trial suspension: Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors (clinicaltrials.gov) - Oct 29, 2013
P3, N=190, Suspended, Sponsor: Tufts Medical Center
Active, not recruiting --> Completed Recruiting --> Suspended
- cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment change: Early Treatment Stratification Based on PET Scan Response to Chemotherapy in Patients With Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Oct 28, 2013
P2, N=71, Completed, Sponsor: Grupo Espa
Recruiting --> Suspended N=250 --> 71
- cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion: Early Treatment Stratification Based on PET Scan Response to Chemotherapy in Patients With Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Oct 28, 2013
P2, N=71, Completed, Sponsor: Grupo Espa
N=250 --> 71 Active, not recruiting --> Completed
- ||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
New P1 trial, Combination therapy, Metastases: Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors (clinicaltrials.gov) - Oct 24, 2013
P1, N=73, Recruiting, Sponsor: PharmaMar
- ||||| Enrollment closed: Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease (clinicaltrials.gov) - Oct 24, 2013
P3, N=1734, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Completed --> Active, not recruiting
- | Avastin (bevacizumab) / Roche
Enrollment change, Combination therapy: Bevacizumab in Extensive Small Cell Lung Cancer (clinicaltrials.gov) - Oct 23, 2013
P2/3, N=143, Completed, Sponsor: Intergroupe Francophone de Cancerologie Thoracique
Completed --> Active, not recruiting N=100 --> 143
- | New P2 trial, Metastases: Androgen Deprivation Therapy in Advanced Salivary Gland Cancer (clinicaltrials.gov) - Oct 23, 2013
P2, N=152, Not yet recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
- ||||| Enrollment closed: Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma (clinicaltrials.gov) - Oct 23, 2013
P3, N=287, Active, not recruiting, Sponsor: Children's Oncology Group
N=100 --> 143 Completed --> Active, not recruiting